Publications by authors named "Merve Atli"
The psychedelic experience can be challenging. There is a need for a structured framework for providing psychological support to individuals with mental health conditions receiving investigational psilocybin treatment. The primary benefit of such a framework is to support a safe and meaningful psilocybin experience.
View Article and Find Full Text PDFRationale: Therapeutic administration of psychedelics has shown significant potential in historical accounts and recent clinical trials in the treatment of depression and other mood disorders. A recent randomized double-blind phase-IIb study demonstrated the safety and efficacy of COMP360, COMPASS Pathways' proprietary synthetic formulation of psilocybin, in participants with treatment-resistant depression.
Objective: While the phase-IIb results are promising, the treatment works for a portion of the population and early prediction of outcome is a key objective as it would allow early identification of those likely to require alternative treatment.
Article Synopsis
- COMP360 is a synthetic psilocybin formulation being tested for treatment-resistant depression (TRD) in a major clinical trial with 233 participants.
- The trial involved different doses of psilocybin (25 mg, 10 mg, and a 1 mg control) combined with therapy, assessing various mental health indicators over three weeks.
- Results showed that the 25 mg dose significantly improved depression and anxiety symptoms compared to the 1 mg dose, with some positive effects from the 10 mg dose; however, the study had limitations, including the lack of an active comparators.